News from PAINWeek 2018: Lofexidine is found particularly suited to mitigate symptoms of rapid opioid withdrawal given its agonist activity at the 5-HT-1A serotonin receptor.
Kenneth J. Bender, PharmD, MA
News from PAINWeek 2018: "Tapering [opioids] is not detoxification," was one among many cautions and recommendations offered during several presentations in Las Vegas, Sept 4-8.
News from PAINWeek 2018: Electroceuticals could replace opioids in the treatment of chronic pain.
From ADA 2018: Two new biomarkers predict CV events independently of conventional risk factors, plus post-hoc analysis of VADT.
Severe hypoglycemia is more prevalent than previously believed and also significantly underreported. Details from 3 studies at ADA 2018.
Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
What is the impact on insulin dose, A1c, body weight of adding GLP-1 RA to a MDI insulin regimen? Three studies from ADA 2018 illuminate.
Should you: Stop a DPP-4i when you start insulin? Prescribe initial triple combination Rx? What about SGLT2i + DPP-4i + MET vs insulin + MET? Find out.
How do 2nd generation basal insulin formulations perform vs their predecessors? We report highlights of 3 important studies from the ADA 78th Scientific Sessions.
Terms such as "opioid McCarthyism" and "witch hunt" were used to express frustration with current opioid regulatory efforts.